

## Refractory Inflammatory Arthritis revised definition and model

1 **SHORT TITLE:** Refractory Inflammatory Arthritis revised definition and model

2 **MANUSCRIPT TITLE:** Refractory Inflammatory Arthritis definition and model  
3 generated through patient and multi-disciplinary professional modified Delphi process

4 **Authors:** Hema Chaplin<sup>1</sup> MSc, Ailsa Bosworth<sup>2</sup> MBE, Carol Simpson<sup>3</sup>, Kate Wilkins<sup>3</sup>,  
5 Jessica Meehan<sup>1</sup> MSc, Elena Nikiphorou<sup>3</sup> MBBS, MRCP, MD(Res), Rona Moss-  
6 Morris<sup>1</sup> PhD, \*Heidi Lempp<sup>3</sup> PhD, \*Sam Norton<sup>1,3</sup> PhD. \*Joint Last Author

7 **Affiliations:** <sup>1</sup>Health Psychology Section, Institute of Psychiatry, Psychology and  
8 Neuroscience, King's College London, London, UK. <sup>2</sup>National Rheumatoid Arthritis  
9 Society; <sup>3</sup>Centre for Rheumatic Diseases, King's College London, London, UK.

10 **Corresponding Author:** Hema Chaplin, [hema.chaplin@kcl.ac.uk](mailto:hema.chaplin@kcl.ac.uk), (+44)20 7188  
11 0192, Health Psychology Section, Institute of Psychiatry, Psychology &  
12 Neuroscience, King's College London, 5th Floor Bermondsey Wing, Guy's Hospital,  
13 London Bridge, London SE1 9RT. ORCID ID: 0000-0002-9402-9669

14 **CRedit Author Statement:** **Hema Chaplin:** Conceptualization, Methodology, Formal  
15 analysis, Investigation, Writing – Original Draft, Visualization, Project Administration,  
16 Funding Acquisition. **Ailsa Bosworth:** Writing - Review & Editing, Project  
17 Administration (Nominal Group), Supervision (Patient Representative). **Carol**  
18 **Simpson:** Writing - Review & Editing, Supervision (Patient Representative). **Kate**  
19 **Wilkins:** Writing - Review & Editing, Supervision (Patient Representative). **Jessica**  
20 **Meehan:** Formal analysis, Writing - Review & Editing. **Elena Nikiphorou:** Writing -  
21 Review & Editing, Supervision (Clinical). **Rona Moss-Morris:** Methodology, Writing -  
22 Review & Editing, Visualization, Supervision (Academic). **Heidi Lempp:**  
23 Conceptualization, Methodology, Formal analysis, Writing – Original Draft, Writing -  
24 Review & Editing, Visualization, Supervision (Academic), Funding Acquisition. **Sam**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Refractory Inflammatory Arthritis revised definition and model

25 **Norton:** Conceptualization, Methodology, Formal analysis, Writing – Original Draft,  
26 Writing - Review & Editing, Visualization, Supervision (Academic), Funding  
27 Acquisition.

28 **Ethical Approval:** Full NHS ethical approval granted in July 2018 by London –  
29 Hampstead Research Ethics Committee (18/LO/1171).

30 **Conflict of Interests:** None

31 **Word Count:** 5,593 plus 294/300 Abstract

32 **References:** 125

33 **Funding:** This paper represents independent research funded by the National Institute  
34 for Health Research (NIHR) Maudsley Biomedical Research Centre at South London  
35 and Maudsley NHS Foundation Trust and King’s College London, in the form of a PhD  
36 Studentship (IS-BRC-1215-20018) for the first author (HC). The views expressed are  
37 those of the author(s) and not necessarily those of the NHS, the NIHR or the  
38 Department of Health and Social Care.

39 **Data availability:** The data generated that support the findings of this study are  
40 available from the corresponding author, HC, upon reasonable request.

41

42

43

44

45

46

## Refractory Inflammatory Arthritis revised definition and model

47

### ABSTRACT

48 **Objective:** Various definitions have been proposed for Refractory Disease in people  
49 with Rheumatoid Arthritis; however, none were generated for Polyarticular Juvenile  
50 Idiopathic Arthritis or involving adult and paediatric multidisciplinary healthcare  
51 professionals and patients. The study aim is to redefine Refractory Disease, using  
52 Delphi methodology.

53 **Methods:** Three rounds of surveys (one nominal group and two online (2019-2020))  
54 to achieve consensus using a predetermined cut-off were conducted voting on: a)  
55 name, b) treatment and inflammation, c) symptoms and impact domains, and d) rating  
56 of individual components within domains. Theoretical application of the definition was  
57 conducted through a scoping exercise.

58 **Results:** Votes were collected across three rounds from Patients, Researchers and  
59 nine multi-disciplinary healthcare professional groups (n=106). Refractory  
60 Inflammatory Arthritis was the most popular name. Regarding treatment and  
61 inflammation, these were voted to be kept broad rather than specifying numbers/cut-  
62 offs. From 10 domains identified to capture symptoms and disease impact, six  
63 domains reached consensus for inclusion: 1) Disease Activity, 2) Joint Involvement,  
64 3) Pain, 4) Fatigue, 5) Functioning and Quality of Life, and 6) Disease-Modifying Anti-  
65 Rheumatic Drug Experiences. Within these domains, 18 components, from an initial  
66 pool (n=73), were identified as related and important to capture multi-faceted  
67 presentation of Refractory Inflammatory Arthritis, specifically in Rheumatoid Arthritis  
68 and Polyarticular Juvenile Idiopathic Arthritis. Feasibility of the revised definition was  
69 established (2022-2023) with good utility as was applied to 82% of datasets (n=61)  
70 incorporating 20 outcome measures, with two further measures added to increase its  
71 utility and coverage of Pain and Fatigue.

## Refractory Inflammatory Arthritis revised definition and model

72 **Conclusion:** Refractory Inflammatory Arthritis has been found to be broader than not  
73 achieving low disease activity, with wider biopsychosocial components and factors  
74 incorporating Persistent Inflammation or Symptoms identified as important. This  
75 definition needs further refinement to assess utility as a classification tool to identify  
76 patients with unmet needs.

77 **Keywords:** Delphi, Multi-disciplinary Healthcare-Professionals, Persistent Symptoms,  
78 Polyarticular JIA, Refractory Disease, Rheumatoid Arthritis.

79

### 80 **What is already known on this topic**

- 81 • In recent years within Rheumatology, parallel bodies of work have reached  
82 similar conclusions regarding the broadening of the Refractory or the wider  
83 Difficult-to-Treat concept.

### 84 **What this study adds**

- 85 • In this paper, we provide a different angle to define, measure, and  
86 conceptualise Refractory Inflammatory Arthritis, using health psychology theory  
87 across Polyarticular Juvenile Idiopathic Arthritis and Rheumatoid Arthritis with  
88 the input of patients, rheumatologists, and multi-disciplinary healthcare  
89 professionals.
- 90 • We support and extend recent definitions of refractory rheumatoid arthritis by  
91 detailing a three-part definition identified as important to both patients and multi-  
92 disciplinary healthcare professionals that can also be applied to Polyarticular  
93 Juvenile Idiopathic Arthritis: 1) Treatment, 2) Inflammation, and 3) Symptoms  
94 and Impact with 18 specific components within 6 domains. The Refractory  
95 Inflammatory Arthritis definition can be operationalised as a classification tool

## Refractory Inflammatory Arthritis revised definition and model

96 using 22 routinely collected data points to identify those who need further  
97 targeted support and treatment.

- 98 • We have applied a biopsychosocial formulation model for Refractory  
99 Inflammatory Arthritis covering perpetuating and protective factors to guide  
100 management strategies and present wider contextual factors involved in the  
101 experience of Refractory Inflammatory Arthritis.

### 102 **How this study might affect research, practice or policy**

- 103 • The development of the Refractory Inflammatory Arthritis definition presented  
104 here included consideration of content and discriminant validity indicators to  
105 provide a clinical and research tool to appropriately classify and measure  
106 Refractory Inflammatory Arthritis with alignment to routinely used measures.

107

108

109

110

111

112

113

114

115

116

117

## Refractory Inflammatory Arthritis revised definition and model

### 118 **Introduction**

119           Refractory Disease (RD) in people with rheumatoid arthritis (RA) refers to the  
120 persistence of disease activity and symptoms despite treatment with multiple drugs  
121 with different mechanisms of action (1), by not achieving low disease activity target  
122 after resistance to two or more biologics (2-5). Previous definitions of RD have focused  
123 on biological underpinnings based mainly on rheumatologists' experiences alone (if  
124 definition generation stated) (1), without consideration of wider psychosocial  
125 contextual components that need to be incorporated from a multi-disciplinary  
126 perspective (6). Therapeutic strategies following a treat-to-target regimen are  
127 generally successful in reducing inflammatory markers, however patient-reported  
128 outcomes have not similarly improved (7, 8).

129           There is evidence that patients' prefer holistic approaches adopting patient-  
130 centred care (9) to avoid the misattribution that symptomatology is solely due to  
131 inflammation. This absence of adequate management strategies ensures persistent  
132 poor patient-reported outcomes. This current project, along with others (2, 5), stems  
133 from a Versus Arthritis workshop in 2015 on the topic of RD that highlighted the need  
134 for a broader definition, incorporating the patient perspective (10). A key knowledge  
135 gap identified was differences in patients and clinicians' definitions of RD. The  
136 biopsychosocial model of RD is poorly understood and refining the concept could  
137 identify novel approaches to adopt a broader perspective to treatment and care.

138           Although current RD research focuses on Rheumatoid Arthritis (RA), there is  
139 clear justification for incorporating Polyarticular Juvenile Idiopathic Arthritis (PolyJIA),  
140 particularly for those now in adulthood, who despite presenting a RD course are  
141 commonly excluded from such research therefore outcomes and impact of disease  
142 and treatment are not fully understood and under recognised (1, 11). Since JIA, and

## Refractory Inflammatory Arthritis revised definition and model

143 in particular the Polyarticular subset, are not benign and self-limiting to childhood (12),  
144 it is important and clinically useful to utilise a common language and approach to  
145 classify and treat these patients similarly to other rheumatic diseases seen in adult  
146 rheumatology care (13).

147         Absence of a systematic approach to identify or evaluate RD means the true  
148 impact and underlying mechanisms remain largely unknown (5). The growing number  
149 of publications on this topic (1) and European Alliance of Associations for  
150 Rheumatology (EULAR) Task Force on the wider concept of Difficult-to-Treat RA (2),  
151 highlights the need to identify, consolidate and implement additional components of  
152 RD. This could assist identifying patients who may benefit from pharmacological  
153 versus non-pharmacological interventions, and address additional strategies, such as  
154 coping and self-management.

155         The aim was to explore and refine the definition of Refractory Disease (RD)  
156 considering the perspectives of healthcare professionals (HCPs) and patients, explore  
157 its meaning and implications, and identify uncertainties about the terminology and  
158 components. The primary objective was to reach a revised consensus definition of RD  
159 in RA and PolyJIA from across multi-disciplinary HCPs and patients' perspectives. The  
160 secondary objective was to assess the feasibility of using the revised definition to  
161 identify RIA in a theoretical application, and revise associated outcome measures if  
162 necessary.

163

164

165

166

## Refractory Inflammatory Arthritis revised definition and model

### 167 **Materials and Methods**

#### 168 **Design**

169 The current study was designed and set up following the Versus Arthritis  
170 workshop (10), comprising of a PhD studentship initiated in 2017. The study involved  
171 three phases: 1) Component Development and 2) Delphi Voting (Figure 1). The  
172 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)  
173 statement guidelines (14) have been adhered to, where appropriate, and checklist for  
174 cohort studies included.

#### 175 **Figure 1: Study Overview**

176 In phase 1, a pool of components was developed based on a multimodal  
177 evidence synthesis. We use the term components to refer to specific facets that  
178 operationalise RD (e.g. synovitis, joint pain).

179 In phase 2, a consensus definition of RD was developed using a Delphi  
180 approach, by surveying panels of experts to achieve a group agreement or  
181 convergence of opinion (15). Components not included in the consensus definition  
182 were retained in a broader conceptual model.

183 In phase 3, a theoretical application of the definition was conducted through a  
184 scoping exercise of rheumatology registries and cohorts.

#### 185 **Component Development**

186 Components of RD were identified from: 1) qualitative interviews and focus  
187 groups with patients and HCPs (16), 2) systematic review of studies of RD in  
188 RA/PolyJIA (1), and 3) review and application of biopsychosocial theories regarding



## Refractory Inflammatory Arthritis revised definition and model

189 chronic illness and persistent symptoms. Firstly, an initial inductive thematic analysis  
190 of 25 patient and 32 HCP interviews conducted between August 2018 and April 2019  
191 identified 17 components for common experiences of RD and persistent symptoms,  
192 whilst an additional seven were patient-specific (including JIA-specific) and four  
193 professional-specific (16) (see unpublished thematic map in S1). This qualitative data  
194 analysis was part of a larger framework analysis, which involves five steps (17, 18): (i)  
195 familiarisation with data, (ii) preliminary thematic analysis to develop initial themes  
196 (presented here and (16)), with further steps occurring later which were: (iii) application  
197 of themes to the whole dataset systematically, (iv) reducing data from transcripts into  
198 summaries and organising these into a matrix (participants by themes), and (v)  
199 identifying patterns and relationships across participants and themes (manuscript in  
200 preparation). Secondly, a systematic review of existing definitions (1) identified three  
201 key elements of RD: 1) treatment, 2) presence or absence of inflammation and 3)  
202 symptoms and impact. These elements were used to group the components and a  
203 three-part definition was explored. Due to the large number of components identified,  
204 and to account for similarities between components, these were grouped thematically  
205 into higher level domains (e.g. disease activity, pain).

206 From the interviews and systematic review, it became clear that some factors  
207 (e.g. reduced mobility) are related to defining RD, whilst others (e.g. social support)  
208 are more relevant to describing poor prognostic, perpetuating or protective elements  
209 related to the experience of RD. These factors can guide treatment strategies in line  
210 with a biopsychosocial formulation (19-21). This is an integrative process that enables  
211 consideration of the complex, interacting factors implicated in development of a  
212 patient's presenting problems to translate the diagnosis into specific, individualised  
213 interventions. This formulation has not previously been applied to RD and could help

## Refractory Inflammatory Arthritis revised definition and model

214 holistically define and explain RD drawing from theoretical models such as Adjustment  
215 to Chronic Illness and Illness Perception Models (22, 23) by aligning identified  
216 concepts to established theories and utilising their terminology and descriptions.  
217 These theoretical models outline the individual behavioural, emotional and cognitive  
218 factors involved in adjustment and adaptation to chronic illness related to the return to  
219 equilibrium following critical illness events/stressors.

220 Findings from these three areas of research were combined during phase 1 to  
221 develop an initial 72 components across 12 domains (see S2) for the Delphi phase  
222 (24), by mapping these concepts onto currently used measures within Rheumatology  
223 (25) such as Musculoskeletal Health Questionnaire (MSK-HQ) (26) and (Child) Health  
224 Assessment Questionnaire ((C)HAQ) (27, 28) to increase utility and validity. The  
225 specific wording of the components was agreed by the wider study team (HC, SN, HL,  
226 CS, KW and EN).

### 227 **Delphi Voting**

228 The Delphi method allows synthesis of the best available information, an  
229 anonymous and iterative process of consensus and validation between key  
230 stakeholders/end-users, with feedback thereby increasing ownership and  
231 engagement (29). Here we used a modified Delphi process through an initial face-to-  
232 face nominal/expert group (September 2019), followed by two rounds of Delphi  
233 surveys online (March-May 2020) (15, 24, 30-32) to vote on preferred terminology and  
234 variables that define RD. Specifically, we sought consensus on (i) preferred name, (ii)  
235 domains to retain in the definition, and (iii) components to retain within each domain.  
236 The process was managed by a non-voting co-ordinator (HC).

237

## Refractory Inflammatory Arthritis revised definition and model

### 238 a) Participants and Sample size

239 A purposive sampling strategy (33) was employed to identify potential Delphi  
240 participants who had experience of RD and/or persistent symptoms in RA/JIA. Three  
241 independent inclusion criteria determined who was invited (33): (1) Patients with  
242 RA/PolyJIA or HCPs within Rheumatology, (2) involvement with RA/JIA patient  
243 organisations or (3) recognized academic career in RD or Persistent symptoms in  
244 RA/JIA. Participants were contacted via e-mail and invited to participate anonymously  
245 online via Qualtrics software (Qualtrics 2020, Provo, UT), to take part in all online  
246 rounds of voting, regardless of whether they had participated in the previous round.  
247 This was to ensure a wide representation and allow recruitment to target during  
248 COVID-19 since many academics and HCPs were redeployed to frontline NHS  
249 services during this time (March and May 2020). Written informed consent was  
250 obtained prior to participation in each round.

251 There is currently no formal sample size calculation in Delphi processes (15).  
252 A pragmatic approach was adopted in line with previous literature (30-32). The  
253 absolute minimum sample size agreed was 12 per round, with at least three members  
254 per participant group (Rheumatologists, other HCPs, Patients, and Researchers). A  
255 target sample size of at least 40 was set for the online surveys based on estimated  
256 95% confidence intervals (CIs) providing sufficient precision to discriminate between  
257 domains rated for inclusion/exclusion from the consensus definition. A total of 89  
258 participants were invited to allow for non-response and attrition.

### 259 b) Data Collection and Analysis

260 Four different stages of analysis were conducted: 1) Name ranking, 2)  
261 Treatment/Inflammation cut-off inclusion, 3) Symptoms/ Impact domain inclusion, and

## Refractory Inflammatory Arthritis revised definition and model

262 4) Component importance rating. Firstly, proportions and 95% CIs were calculated to  
263 determine the name preference voting. Participants indicated their top three name  
264 choices in each round with the choice receiving majority vote in the final round  
265 proposed as the final definition name. Secondly, for the treatment and inflammation  
266 questions, there was a need to achieve consensus on whether the definition needs to  
267 specify distinct cut-offs or include a broader statement (see S3). Options receiving  
268 most responses in the first round were taken forward to the next round. Thirdly, for  
269 each domain participants were asked to rate whether the domain needed inclusion on  
270 a nine point Likert scale (1='Definitely Not Include' to 9='Definitely Include') (15). In  
271 line with previous literature (30-32), a priori level of agreement was required ( $\geq 70\%$   
272 rating domains 7-9 for inclusion and 1-3 for exclusion). Mean and 95% CIs were also  
273 estimated to allow consideration of the certainty of domain inclusion or exclusion.

274 Finally, for each component, participants were asked to rate how related the  
275 component is to assess a) Refractory Arthritis, and b) Disease flare (-3='Highly  
276 Unrelated' to 3='Highly Related'), and to provide comments to clarify component  
277 meaning (30) (see S3). Inclusion of components in the consensus definition was based  
278 on: a) high mean related total scores for Refractory Arthritis, and b) mean difference  
279 and effect sizes between ratings for Refractory Arthritis and Disease Flare. This  
280 second criterion allowed discriminant validity to be established to ensure selected  
281 components appropriately differentiated between these two constructs. Scores within  
282 participant groups were also considered to identify differences across groups and  
283 ensure that components rated as important by one group, particularly patients and  
284 rheumatologists, were not excluded.

285 Several exploratory subgroup analyses were undertaken to assess differences  
286 across the four different role groups (Patients, Rheumatologists, Other HCPs and

## Refractory Inflammatory Arthritis revised definition and model

287 Researchers), in terms of representation across the different rounds of voting in both  
288 those who started and completed all voting, and in ranking and scoring of the  
289 symptoms and impact domains for inclusion. To assess whether there were any  
290 differences across the different rounds of voting regarding the sociodemographic  
291 characteristics such as years of rheumatology experience and adult versus paediatric  
292 trained, one-way ANOVAs were conducted for continuous variables and Fishers exact  
293 tests for categorical variables due to low numbers per category. To assess differences  
294 across the clinical role groups (Rheumatologists, Patients and Other Healthcare  
295 Professionals) in voting on domains for inclusion, simple linear regressions for each  
296 domain were conducted with additional tests and contrasts to determine significant  
297 variability.

298 The minimum response for each domain was set at  $\geq 75\%$  (32) and only whole  
299 domains could be missing rather than components within domains due to the software  
300 used for data collection, further analysis such as mixed-effect models was not required  
301 to adjust for missing data. Additional analysis of the related ratings to generate Item-  
302 level Content Validity Indexes (I-CVI) (34) was conducted to ensure the final definition  
303 is composed of an appropriate components to adequately represent the construct of  
304 interest whilst also considering inter-rater agreement to reflect consensus. The final  
305 chosen components were then again initially mapped onto to routinely used measures  
306 identified from literature searching (35, 36).

### 307 **Theoretical Definition Validation**

308 A theoretical validation through literature scoping of worldwide RA and JIA  
309 registries/cohorts was undertaken (between October 2022 and February 2023) to  
310 highlight what components and domains of the definition could be utilised, and to  
311 identify alternative measures if possible. The feasibility and application of using the

## Refractory Inflammatory Arthritis revised definition and model

312 identified outcome measures or data points to identify RIA was then explored using  
313 frequencies. Websites of relevant rheumatology organisations were screened for  
314 details of relevant registries and/or cohorts with PROMs for RA and JIA. This was  
315 supplemented by internet searches of rheumatology registries and cohorts to identify  
316 details of the data collected in the registries which was extracted from study-specific  
317 websites or publications. This initial searching uncovered summary studies that have  
318 a similar scoping aim and captured some of the required data (36-39). A summary  
319 table was produced to highlight the data captured across the included registries and  
320 cohort studies (36).

### 321 **Patient and Public Involvement**

322 Patients were involved in the design, conduct, reporting, and dissemination of  
323 this research, in which AB, CS and KW have been integral at all stages as Patient  
324 Research Partners. Numerous others were involved in the design of this project which  
325 evolved through various stages of involvement with people with RA and PolyJIA. Both  
326 diagnoses were included because early patient and public involvement work revealed  
327 that RD is a problem across both age and disease groups.

### 328 **Results**

#### 329 **Sample characteristics**

330 Across the three rounds, 106 votes were cast in this Delphi study as seen in  
331 Table 1. Due to anonymity, the total number of unique participants or number of rounds  
332 each participant voted in cannot be determined. There were no differences in  
333 participant characteristics (e.g. Rheumatology experience or diversity of roles)  
334 between each round for those that completed, nor between those who dropped out  
335 (n=3 each online round) (see S4). In Round One, duplicate data for two responses

## Refractory Inflammatory Arthritis revised definition and model

336 (e.g. started survey on one device then continued on another) was removed, otherwise  
337 attrition occurred such that domain completion rates were between 90-100%, therefore  
338 meeting the pre-determined minimum response rate. In Round Two, the attrition  
339 occurred after the name ranking questions, with otherwise complete data.

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

## Refractory Inflammatory Arthritis revised definition and model

356 **Table 1:** Characteristics of Delphi Voters (n=106)

	Face-to-Face Nominal Group (N = 13)	Online Delphi Round One (N = 40)	Online Delphi Round Two (N = 53)
Role, n (%) <sup>†</sup>			
Rheumatologist	5 (38.5%)	11 (27.5%)	17 (32.1%)
Nurse	1 (7.7%)	4 (10%)	3 (5.7%)
GP	1 (7.7%)	3 (7.5%)	3 (5.7%)
Pharmacist	0	1 (2.5%)	3 (5.7%)
Psychologist	0	2 (5%)	3 (5.7%)
Podiatrist	0	1 (2.5%)	1 (1.9%)
Physiotherapist	0	3 (7.5%)	5 (9.4%)
Occupational Therapist	0	2 (5%)	4 (7.6%)
Patient Representatives	3 (23.1%)	8 (20%)	10 (18.9%)
Researcher*	3 (23.1%)	4 (10%)	3 (5.7%)
Social Worker	0	1 (2.5%)	1 (1.9%)
Number of years' experience in Rheumatology, mean (SD)			
Professionals	15.10 (12.07)	15.59 (11.30)	16.07 (8.62)
Patients	21.33 (16.29)	25.62 (14.17)	28 (12.29)
Predominantly trained/worked <sup>‡</sup> , n (%)			
Adult	9 (90%)	20 (62.5%)	29 (67.4%)
Paediatric	1 (10%)	6 (18.75%)	7 (16.3%)
Both	0	6 (18.75%)	7 (16.3%)
Received specific MSK training <sup>‡</sup> , n (%)			
Yes	6 (60%)	24 (75%)	32 (76.7%)
No	4 (40%)	8 (25%)	10 (23.3%)

357 <sup>†</sup>Although participants were allowed to select multiple roles, the main role is reported here.

358 <sup>‡</sup>Professional roles only were reported. \*Researchers covered the following disciplines:

359 Radiology, Psychology, Medical Sociology, Rheumatology and Health Services, Statistics and

360 Epidemiology.



## Refractory Inflammatory Arthritis revised definition and model

### 361 **Name Preference Voting**

362 During the nominal group workshop (one missing voter due to late arrival), ten  
363 terms were voted on for the name of the definition, of which RD, Persistent Disease  
364 and Treatment Resistant were the most popular (see S5). Moreover, participants  
365 suggested that the terminology should include Part A and Part B elements to form  
366 different name iterations to be voted on subsequently, with the following additions:  
367 'Ongoing', 'Inflammatory Arthritis', 'Syndrome', 'Inflammation' and 'Symptoms'.  
368 Consequently, the top three preferences from Round One online voting were  
369 combined to create nine names involving all combinations of the label (e.g. refractory,  
370 resistant) and target (e.g. inflammatory arthritis, disease), which participants were  
371 asked to again select their top three in Round Two (see S5). Refractory Inflammatory  
372 Arthritis received the majority vote (25% of votes), followed by Persistent Inflammatory  
373 Arthritis (19% of votes). There was slight disparity in the top preference between  
374 Patients and the other three groups as Persistent Inflammatory Arthritis received  
375 21.6% of the votes by Patients whilst both RIA and RD received 15%.

### 376 **Definition of Refractory Inflammatory Arthritis**

377 Based on the Delphi process (detailed below), a consensus definition for RIA  
378 is proposed in Table 2. This three-part definition covers the core elements identified in  
379 phase 1: 1) treatment, 2) inflammation presence (Persistent Inflammation) or absence  
380 (Persistent Symptoms) and 3) symptoms and impact, which comprises 18 components  
381 across 6 domains to capture the presentation and experience of RIA. To identify a  
382 patient as having RIA, at least one component from each part 1-3 need to be met, and  
383 initial suggestions for assessment for each component included 20 data points (see  
384 S10) such as (C)HAQ (27, 28), MSK-HQ (26), Consultation / Joint Examination /

## Refractory Inflammatory Arthritis revised definition and model

385 Clinical Notes (40) and EuroQol 5-Dimensions (EQ5D) (41). These are based on  
386 commonly used measures in paediatric and adult rheumatology clinical cohorts and  
387 registers (35, 36), with suggested cut-offs or scoring direction on continuous measures  
388 and were explored further in the theoretical validation exercise.

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

Refractory Inflammatory Arthritis revised definition and model

405 **Table 2:** Revised consensus definition of Refractory Inflammatory Arthritis

REFRACTORY INFLAMMATORY ARTHRITIS	
Part 1: Treatment	DESPITE following Treat-to-Target Strategy using $\geq 1$ csDMARDs, and $\geq 1$ anti-TNF, bDMARDs and/or tsDMARDs with different mechanisms of action
Part 2: Inflammation	Synovial inflammation is PRESENT (Persistent Inflammation) or ABSENT (Persistent Symptoms) as determined by inflammatory markers, physical examination and imaging or composite disease activity
Part 3: Symptoms and Impact	<p>PLUS <math>\geq 1</math> of the following:</p> <ol style="list-style-type: none"> <li>1. <u>Disease Activity</u> <ol style="list-style-type: none"> <li>a. Persistently high inflammation and/or symptoms e.g. with or without fluctuations for at least two consecutive clinical visits over the period of at least six months</li> <li>b. Disease Activity not captured by DAS28 (hands, shoulders, wrists, elbows and knees) including involvement of other joints (hips, temporomandibular, feet), extra-articular manifestations or other inflammatory features (vasculitis, uveitis, tendonitis or enthesitis) or non-inflammatory features (muscle weakness or cachexia)</li> <li>c. Repeated need of short course steroid tablets or intra-articular injections due to inflammatory arthritis manifestations, that may or may not control flare and localised swelling</li> </ol> </li> <li>2. <u>Joint Involvement</u> <ol style="list-style-type: none"> <li>a. Joint stiffness during the day (longer than 30-60 minutes upon waking)</li> <li>b. One or two persistently active/affected joints despite acceptable control in other joints</li> <li>c. Accrued damage due to inflammation - Joint erosion(s), deformity(ies) or restrictions in range of movement</li> </ol> </li> <li>3. <u>Pain</u> <ol style="list-style-type: none"> <li>a. Pain in joints e.g. hands and feet</li> <li>b. Pain during the day and/or night</li> <li>c. Pain Interference impacting on quality of life</li> </ol> </li> <li>4. <u>Fatigue</u> <ol style="list-style-type: none"> <li>a. Lack of physical energy resulting in difficulties conducting daily activities e.g. washing, dressing</li> <li>b. Lack of mental energy leading to difficulties with concentration and memory</li> </ol> </li> <li>5. <u>Functioning and Quality of Life</u> <ol style="list-style-type: none"> <li>a. Problems with self-care e.g. washing/dressing</li> <li>b. Inability to perform desired activities e.g. hobbies, social, work</li> <li>c. Poor physical function e.g. lack of strength, dexterity, grip</li> <li>d. Reduced mobility and/or Problems walking, standing, or climbing stairs e.g. driving, use of public transport, needing to sit</li> <li>e. Disease-related distress e.g. psychological distress related to burden of disease including Physical related, Emotional, Social, Treatment or Healthcare Distress</li> </ol> </li> <li>6. <u>cs/b/tsDMARD Experiences</u> <ol style="list-style-type: none"> <li>a. Primary inefficacy (no response to DMARD at all) and/or Secondary inefficacy (developed DMARD resistance over time)</li> <li>b. Experience of multiple occurrences of inefficacy, intolerability, or discontinuation</li> </ol> </li> </ol>

406

## Refractory Inflammatory Arthritis revised definition and model

407 An overview of the phases of definition development including refinements and  
408 voting results during Delphi rounds are presented in S6. Nominal group attendees  
409 agreed all 12 domains (85-100%) to be included in the next stage of voting. All  
410 domains were voted as related to RD, with Pain, DMARD Experiences, Joint Activity  
411 and Co-morbidities rated the most highly, whilst Poor Quality Sleep, Steroid Use and  
412 Dependency and Social Functioning and Quality of Life were rated the lowest.  
413 Discussion included the addition of Healthcare Utilisation (eight components) to the  
414 Steroids domain, with refinements/additions to eight other components e.g. sex,  
415 benefits, variability, assessment of feet and removal of one component (“unable to  
416 relax easily”). They also stated the importance of investigating other undiagnosed  
417 underlying reasons for these symptoms in case these treatable causes are driving  
418 suspected RD e.g. thyroid issues causing fatigue. Further discussions with the study  
419 team and Health Psychology Group at KCL took the final total count of components  
420 identified for voting to be 73 across 10 domains as the three Functioning and Quality  
421 of Life Domains were condensed into one domain (see S2).

422 In Round One online voting, for Parts One and Two regarding Treatment and  
423 Inflammation factors, the consensus was for these to be kept broad (65-70%) as  
424 originally proposed rather than specifying fixed cut-offs (Tables 2 and 3). As seen in  
425 Figure 2, seven domains in Round One met consensus criteria for inclusion ( $\geq 70\%$   
426 rating the domain between 7-9 for inclusion on the 1-9 scale) for Part 3 Symptoms and  
427 Impact (see S7 for data and decisions). Of these, three were clearly above this  
428 inclusion threshold, whilst the remaining four indicate uncertainty as to the  
429 generalisability of inference. The remaining three domains did not reach agreement  
430 whether to include or exclude, and when converted into rankings were consistently the  
431 lowest across the different role groups (see S8). Rheumatologists and Other

## Refractory Inflammatory Arthritis revised definition and model

432 Healthcare Professionals ranked Joint Activity highest, then Stiffness and Disease  
433 Activity in their top three. Whereas Patients ranked Disease Activity and Fatigue jointly  
434 highest with Pain third as their top three, therefore more symptom focussed.  
435 Researchers ranked Disease Activity highest then Pain and Functioning and Quality  
436 of Life as joint second in their top three.

### 437 **Figure 2:** Round One Domains and Round Two Components Inclusion

438 Regression analyses revealed no differences in mean include scores across  
439 the training specialties (Adult vs Paediatric vs Both), however there were some  
440 subtleties in the domains reaching criteria for inclusion. Analyses highlighted the  
441 different priorities and considerations for HCPs with paediatric versus adult patients.  
442 For Paediatric professionals, Fatigue (66.67%) and DMARD experiences (33.33%) did  
443 not reach inclusion criteria, with Pain (66.67%) and Functioning and Quality of Life  
444 (66.67%) also falling short for those trained in Both. There was greater variability in  
445 responses for the group that had received both Adult and Paediatric training, who were  
446 heterogenous population that encompassed a mixture of Researchers,  
447 Rheumatologists, a Physiotherapist and a GP.

448 From Round One voting, 30 components from the seven included domains  
449 were retained based on mean related scores and the difference with flare, and I-CVI  
450 scores. The core study team (HC, SN, HL) then discussed and prioritised those with  
451 higher mean related score, followed by those with medium-to-large difference whilst  
452 considering the I-CVI and any free text comments regarding modification and  
453 clarification (see S9 & S10). This resulted in final data driven selection of 16  
454 components, through combining two domains (Joint Activity and Stiffness into Joint  
455 Involvement) and combining some components (e.g. Pain during the day and Pain  
456 during the night combined into Pain during day and/or night).

## Refractory Inflammatory Arthritis revised definition and model

457 Thirteen components, not achieving consensus in round one, were taken  
458 forward to Round Two (see S2): nine components from Sleep, Co-morbidities and  
459 Wider Involvement Outside of Joints and Healthcare/Medication Utilisation and  
460 exploration of four exclusion criteria from components voted in Round One as highly  
461 unrelated. From Round Two, only two components out of the 13 voted upon reached  
462 the required criteria for inclusion (see S7 and Figure 2), taking the total number of  
463 components achieving consensus for inclusion to 18. The core research team decided  
464 not to hold a third round of online voting as only three components had not achieved  
465 consensus for inclusion or exclusion. Given each included domain consisted of at least  
466 two components, these three components were excluded from the definition.

### 467 **Refractory Inflammatory Arthritis (RIA) Conceptual Model**

468 A wider conceptual model was generated by the core research team to allow  
469 for consideration of the relationship between the domains and components excluded  
470 from the consensus definition and RIA, based on the Phase 1 development work (1,  
471 16). The concepts and examples given here are based on findings from the systematic  
472 review highlighting the role of other contributing factors such as Serology and fixed  
473 disease factors such as disease duration (1) and qualitative work on patients' and  
474 HCP' experiences of RIA (16) (see S1) such as social support and independence  
475 which included elements such as adjustment, resilience and illness/treatment beliefs  
476 which align with general theories of perceptions and adjustment to long-term illness.  
477 This followed a Biopsychosocial Formulation (19, 20) (see Figure 3), with the Definition  
478 of RIA with Persistent Symptoms or Inflammation at the core, surrounded by  
479 Predisposing, Poor Prognostic, Perpetuating and Protective factors.

480 **Figure 3:** Proposed Conceptual Model of Refractory Inflammatory Arthritis

## Refractory Inflammatory Arthritis revised definition and model

481           Some of the Precipitating factors are the same to RA/PolyJIA generally, whilst  
482 Poor Prognostic factors suggest some mechanisms identified for those that then lead  
483 to have a more refractory course, which therefore cannot be modified. However,  
484 building on these symptoms and impact are the Protective and Perpetuation factors  
485 that describe some of the biopsychosocial mechanisms underpinning why some  
486 patients may experience negative and worsening impact of RIA (Perpetuating) on their  
487 daily lives whilst others appear to manage and live with reduced impact (Protective),  
488 despite experiencing RIA with Persistent Symptoms or Inflammation. The allocation of  
489 factors is individual and based on the Impact Triad (42), which includes the patient's  
490 perceived severity, importance and ability to self-manage/cope with the factor or  
491 symptom to determine patient priorities from the level of perceived impact. The  
492 Protective and Perpetuating factors can be modified and targeted to reduce disease  
493 impact and improve quality of life. This conceptual model allows for the identification  
494 of potential risk factors and interventional targets that Rheumatologists and other  
495 HCPs can consider as part of the shared decision-making process of deciding which  
496 treatments may be most appropriate for patient.

### 497 **Theoretical Definition Validation**

498           A total of 61 registries/cohorts were identified across 63 publications in the  
499 scoping exercise (36, 37, 43-104) (detailed in S11), of which most were RA (n=43,  
500 70.5%) and in Europe (n=39, 63.9%). Across the registries/cohorts identified, the four  
501 most complete components from the 20 initial data points (see S12) were Joint Count  
502 (n=61, 100%), ESR/CRP (n=60, 98%), (C)HAQ (n=58, 95%) and Clinical  
503 notes/information (n=55, 90%) with the four most missing components being the Work  
504 and Social Adjustment Scale (WSAS), RA Distress Scale (RADS), and Bristol RA

## Refractory Inflammatory Arthritis revised definition and model

505 Fatigue (BRAf) which were not collected in any, and MSK-HQ was only collected in  
506 one (59).

507 The registries/cohorts contained between 6-15 (27-68%) of the proposed data  
508 components (out of 20). For each part of the definition, the following could be applied:  
509 Part One: Treatment (82%), Part Two: Inflammation (100%), Part Three: Symptoms  
510 and Impact (100%), and for each subdomain (as only one component is necessary):  
511 3.1) Disease Activity (100%), 3.2) Joint Involvement (100%), 3.3) Pain (87%), 3.4)  
512 Fatigue (26%), 3.5) Functioning and Quality of Life (98%), and 3.6) DMARD  
513 Experiences (92%). Therefore, the RIA definition could be applied to 82% of the  
514 identified registries/cohorts. Several appropriate substitutions were used in these  
515 studies of which the most common relevant measures that could be substituted were  
516 the Patient Global VAS (PGA) (n=40) and SF-36 (n=19). By adding these two  
517 measures, the following increases in the application of the definition for subdomains  
518 of Part Three were found to be: 3.3) Pain (98%) and 3.4) Fatigue (93%), which is the  
519 most marked increase.

520 This scoping exercise established the theoretical feasibility of applying the RIA  
521 definition by highlighting which data points are collected or missing. None collected all  
522 the initial 20 measures, although the RIA definition as it is initially proposed could be  
523 applied to 50 registries/cohorts (82%) if only one item from each part is satisfied and  
524 to 10 registries/cohorts (16%) if an item from each subdomain of Part Three is met to  
525 identify RIA. With the addition of PGA and SF-36, 45 registries/cohorts (74%) capture  
526 one item from each of the six subdomains of Part Three increasing its utility and  
527 coverage of all subdomains as discussed below for symptom-based stratification.  
528 Therefore following the scoping exercise, SF-36 and PGA was included in the  
529 assessments mapped on to the RIA definition as seen in Table 3, as general measures



## Refractory Inflammatory Arthritis revised definition and model

530 to substitute for missing disease-specific measures (105, 106). Disease and symptom  
531 specific measures, e.g. Pain VAS rather than PGA, need to be prioritized by assessors  
532 but to increase application and utility, relevant generic measures may be appropriate  
533 alternatives.

## Refractory Inflammatory Arthritis revised definition and model

**Table 3:** Assessments mapped onto Refractory Inflammatory Arthritis definition

RIA Definition	Assessment Methods (including cut-offs)
Part 1: Treatment	Treatment History ( $\geq 1$ csDMARDs, and $\geq 1$ anti-TNF/b/tsDMARDs) (40)
Part 2: Inflammation	Abnormal/Raised Inflammatory markers (ESR / CRP based on the local laboratory standards or ESR $>10$ and CRP $>3$ based on mean values) (40, 107) Physical examination (T/S/A/LJC) $\geq 1$ (40, 108) Imaging of Synovial Inflammation (Ultrasound or MRI) (40)
Part 3: Symptoms and Impact	1. <u>Disease Activity</u>
	Clinical notes / Consultation (or mention of extra-articular manifestations etc) / Medical and Treatment History (40) DAS28 $>3.2$ (109) or SDAI $>11$ (110) RAID (scoring higher on Q5) (111)
	2. <u>Joint Involvement</u>
	MSK-HQ (scoring 0-2 on Q1 and/or 2) (26) Consultation / Physical examination (TJC/SJC) $\geq 1$ / Clinical Notes (40, 108) Stiffness Assessment ( $>30$ minutes duration) (112) Imaging of Damage/Erosions Score (Radiographs) (40)
	3. <u>Pain</u>
	MSK-HQ (scoring 0-2 on Q1 and/or 2) (26) Pain VAS $>3.5$ (113) or PGA $\geq 3$ (106) EQ5D (scoring 2 or 3 on Q4) (41) RAID (scoring higher on Q1) (111) Pain Scale of SF-36 (average of recoded items 21 and 22) (105)

## Refractory Inflammatory Arthritis revised definition and model

RIA Definition	Assessment Methods (including cut-offs)	
Part 3: Symptoms and Impact	4. <u>Fatigue</u>	BRAF (Higher total score and on items) (114) Fatigue VAS >2.0 (115) or PGA ≥3 (106) MSK-HQ (scoring 0-2 on Q10) (26) RAID (scoring higher on Q3) (111) Vitality Scale of SF-36 (average of recoded items 23, 27, 29 and 31) (105)
	5. <u>Functioning and Quality of Life</u>	(C)HAQ (≥1 total score to represent moderate-to-severe disability) (116) EQ5D (scoring 2 or 3 on Q1-3 and Q5) (41) Physical Functioning Scale of SF-36 (average of recoded items 3-12) (105) Role Limitations Scale of SF-36 (average of recoded items 13-19) (105) Social Functioning Scale of SF-36 (average of recoded items 20 and 32) (105) WSAS (higher total score and on items 1-4) (117) MSK-HQ (scoring 0-2 on Q3-7 and Q11) (26) RAID (scoring higher on Q2 and Q6) (111) RADS (118) Emotional wellbeing scale of SF-36 (average of recoded items 24-26, 28, 30) (105) or SF-36 (scoring ≤38 on the Mental Component Subscale) (66) Consultation (40)
	6. <u>cs/b/tsDMARD Experiences</u>	Clinical notes / Treatment and DAS28 History / Consultation (or mention of steroid use and reasons for DMARD changes) (40)

Please Note: DAS28: Disease Activity Score 28 joint count, SDAI: Simplified Disease Activity Index, RAID: Rheumatoid Arthritis Impact of Disease, (C)HAQ: Child or Adult Health Assessment Questionnaire, MSK-HQ: Musculoskeletal Health Questionnaire, VAS: Visual Analogue Scale, EQ5D: EuroQol 5-Dimensions, BRAF: Bristol RA Fatigue Scale, WSAS: Work and Social Adjustment Scale, RADS: Rheumatoid Arthritis Distress Scale

## Refractory Inflammatory Arthritis revised definition and model

### 1 **Discussion**

2           This study presents the development of a consensus definition for Refractory  
3 Inflammatory Arthritis (RIA) with Persistent Symptoms or Inflammation across multi-  
4 disciplinary HCPs and patients, in line with the study aim and objectives. This three-  
5 part definition covers core elements of treatment, presence or absence of  
6 inflammation, and symptoms and impact, including: 1) Disease Activity, 2) Joint  
7 Involvement, 3) Pain, 4) Fatigue, 5) Functioning and Quality of Life, and 6) DMARD  
8 Experiences. This captures the multi-faceted presentation and experience of RIA in  
9 RA and PolyJIA populations covering biological and psychological symptoms. This  
10 work independently validated and supports the growing body of evidence to  
11 understand and refine the concept of Refractory Disease (RD), notably the EULAR  
12 Difficult-to-Treat Task Force and others (2, 4, 5, 119-121). It is worth noting that the  
13 current study was designed and set up in 2017, as part of a Health Psychology PhD  
14 programme of research before publication of the EULAR Difficult-to-Treat Task Force  
15 work. These parallel bodies of work have reached similar conclusions that a broader  
16 definition needs to include treatment, symptoms (including inflammation) and impact  
17 as part of the RIA concept, however these have been more generally stated in the  
18 EULAR definition (2, 120).

19           Here we suggest an extension to this general criterion recently proposed by  
20 detailing a three-part definition identified as important to both patients and multi-  
21 disciplinary HCPs with 18 specific components within 6 domains that can be  
22 operationalised. Additionally, our definition has been derived through a different  
23 evidence synthesis approach, e.g. systematic review, qualitative interviews,  
24 application of biopsychosocial theory and Delphi consensus voting, which is a  
25 different, more methodologically rigorous approach than a survey, scoping literature

## Refractory Inflammatory Arthritis revised definition and model

26 review and agreement process (consensus not defined) (2). Another distinguishing  
27 feature of this study is participation of a larger number of patients, multi-disciplinary  
28 professionals from nine relevant specialties and researchers across both adult and  
29 paediatric services to include PolyJIA within this refractory concept, compared to the  
30 Difficult-To-Treat Taskforce which consisted of rheumatologists predominantly, two  
31 patient partners, one health professional (not defined), one psychologist, one  
32 pharmacist and one occupational therapist (2). Another feature was the selection of  
33 the name for the definition, which fits with the common use of the term Refractory in  
34 the literature (1), and the distinction with Difficult-To-Treat Disease (120).

35 For Paediatric professionals, Fatigue and DMARD experiences did not reach  
36 inclusion criteria. However, it is important to bear in mind the lower sample sizes for  
37 the Paediatric and Both groups compared to the Adult sample, therefore no firm  
38 conclusions can be drawn to suggest these domains and their components would  
39 need to be removed for a paediatric specific definition. Given there were no significant  
40 differences in the domain means, it seems that the proposed definition based on the  
41 whole group scores may be appropriate for use in the paediatric PolyJIA population  
42 as well, and requires further exploration. This study has shown that it is feasible to  
43 include both adult and paediatric professionals and patients. Given the relative rarity  
44 of JIA and those specialising in paediatric and adolescent rheumatology, the use of a  
45 transdiagnostic approach in future research can be advantageous.

46 This scoping exercise established the feasibility of applying the revised  
47 definition of RIA in line with the second objective to 61 identified datasets, which found  
48 that the definition has good utility. The RIA definition could be applied to 82% of  
49 datasets and has been revised to include suggestions for 22 data points that are  
50 routinely collected in clinical practice and research studies. The main outcome that

## Refractory Inflammatory Arthritis revised definition and model

51 limited the application of the definition was Treatment History, as only a single item  
52 was required for Part One whereas for Parts Two and Three there were multiple  
53 alternatives. This lack of reporting for treatment history would also be a limitation for  
54 the other definitions that are based on multiple bDMARDs (2, 4). The findings fit well  
55 with a systematic review of outcome measures used in 88 RA registries and long-term  
56 observational studies where disease activity (mainly DAS28) and physical functioning  
57 (mainly HAQ) was consistently recorded in included studies whilst there was  
58 heterogeneity in the patient-centred outcomes for symptom burden and psychosocial  
59 ramifications (2, 122). This type of validation was not conducted with the original  
60 definition of Refractory Disease (3), nor to the same degree with the most recent  
61 definitions (2).

62 Unlike previous definitions (1, 2), the development of the new RIA definition  
63 presented in this paper included consideration of content and discriminant validity  
64 indicators (I-CVI and mean difference with flare) and therefore provides a tool to  
65 appropriately identify and measure RIA, alongside a conceptual model of related  
66 factors. This RIA definition could serve as a clinical or research checklist with the  
67 components aligned to routinely used measures (35, 36), as listed in Table 3 to enable  
68 identification of aspects requiring further support e.g. low HAQ indicating issues with  
69 functioning and quality of life (Domain 5) could prompt a referral to Occupational and  
70 Physiotherapies (8). The use of cut-offs increase outcome interpretability, making the  
71 RIA definition more meaningful and applicable in both in clinical practice and research,  
72 by allowing data to be compared and pooled (123). A criticism of the Difficult-to-treat  
73 definition (2) is the subjective character of the third criterion which meant not all  
74 elements could be applied to a dataset as it was deemed too subjective to extract from  
75 the available data (124). Messelink and colleagues also highlighted that whether “the

## Refractory Inflammatory Arthritis revised definition and model

76 management of patients is perceived as problematic” will most often not be routinely  
77 noted in health records and stated this lack of clarity and objectivity to be a key  
78 challenge in future research using the Difficult-to-treat definition (2).

79         Within the RIA model presented here, Protective and Perpetuating Factors  
80 suggest some of the underlying biopsychosocial mechanisms that may explain why  
81 some patients experience negative and worsening impact of RIA in their lives  
82 (Perpetuating) whilst others have minimal or less impact despite experiencing RIA  
83 (Protective). By identifying the specific Protective and Perpetuating factors deemed to  
84 have an impact through biopsychosocial formulation for each patient (19, 20, 42), it  
85 may be possible to address these wider clinical and sociodemographic factors that  
86 contribute to non-response to treatment, which is important to identify those requiring  
87 additional non-pharmacological support from a multi-disciplinary team (6, 8, 21, 121).  
88 This fits with subsequent EULAR work which identified multiple contributing factors, a  
89 high burden of disease and the heterogeneity of Difficult-To-Treat RA (125),  
90 suggesting that these factors should be identified in daily practice in order to tailor  
91 therapeutic strategies further to the individual patient with the RIA model providing  
92 such a framework.

93         Several limitations and potential bias within the current study should be  
94 discussed. It would have been useful to have a patient and clinician included in the  
95 core study team discussions during the delphi voting iterations following nominal group  
96 discussions however this process was data driven with little subjective decision  
97 making made by the researchers involved. Since most domains met pre-defined  
98 inclusion criteria in the first round, the process was less iterative than previous Delphi  
99 studies (31, 32), without continuous re-voting on the same components and due to  
100 anonymity the team was unable to provide individualised feedback to voters. This may

## Refractory Inflammatory Arthritis revised definition and model

101 be a consequence of online data collection, rather than a face-to-face meeting with  
102 further deliberation. However, the completion of an online questionnaire enabled a  
103 larger number of participants to take part, specifically during the first COVID-19 wave.  
104 There was a predominant bias towards participants from the UK followed by Europe  
105 and caution is required for applicability of this definition in other countries. This project  
106 determined a preliminary definition of RIA, requiring further validation to explore  
107 staging within the definition to account for severity and differences between conditions  
108 and countries. The refinement could be achieved through assessment of retrospective  
109 cohorts and datasets from the UK, followed by different global cohorts.

### 110 **Conclusion**

111 Within Rheumatology, parallel bodies of work have reached similar conclusions  
112 regarding the broadening of the Refractory or the wider Difficult-to-Treat concept. The  
113 authors provide a different angle to define, measure, and conceptualise Refractory  
114 Inflammatory Arthritis (RIA), using health psychology theory across PolyJIA and RA  
115 with the input of patients, rheumatologists, and multi-disciplinary HCPs. The multi-  
116 factorial definition and model proposed can help to identify patients experiencing RIA  
117 where inflammation and/or symptoms persist despite treatment and allow for the  
118 consideration of wider contextual factors that may not be targeted by pharmacological  
119 treatments. Future work could explore the application and validity of the RIA definition  
120 in other Rheumatic Musculoskeletal Diseases, both adult and juvenile variations.  
121 Appropriate adult and paediatric measures have been proposed to measure RIA (25),  
122 which require further validation to assess practicality and feasibility, and could initiate  
123 development of classification criteria.

124



## Refractory Inflammatory Arthritis revised definition and model

125 **Acknowledgements:** Thank you to all the patients and healthcare professionals that  
126 took part in the Delphi voting and to the Refractory Delphi Nominal Group which  
127 comprised of Ailsa Bosworth, Sam Norton, Heidi Lempp, Katie Bechman, Wendy  
128 Olsder, Di Skingle, Flora McErlane, Louise Parker, Elena Nikiphorou, Lianne Kearsley-  
129 Fleet, Simon Black, Adam Young, and Kevin Davies. Finally, thank to you to Nora Ng,  
130 James Galloway, Ian Scott, Debajit Sen, and Rachel Tattersall for support and help  
131 recruiting to the qualitative study. For the purposes of open access, the author has  
132 applied a Creative Commons Attribution (CC BY) licence to any Accepted Author  
133 Manuscript version arising from this submission.

134

### 135 **Supplementary Material Legends (11)**

136 **Supplementary Figure S1:** Key components of Refractory Disease and Persistent  
137 Symptoms identified by Patients and Rheumatologists during Qualitative Interviews.

138 **Supplementary Data S2:** Lists of Components and Domains presented during a)  
139 Nominal Group, b) Round One Online Voting, and c) Round Two Online Voting

140 **Supplementary Data S3:** Example of Delphi Voting Questions (Round One Online)

141 **Supplementary Figure S4:** Analysis of Participants across Delphi Rounds

142 **Supplementary Data S5:** Options for Name preference voting with Proportions and  
143 95% Confidence Intervals

144 **Supplementary Figure S6:** Overview of Definition Development and Refinement

145 **Supplementary Tables S7:** Statistics for Round One and Two Components  
146 Considered for Definition

147 **Supplementary Figure S8:** Round One Rankings of Domains by Role Group

## Refractory Inflammatory Arthritis revised definition and model

148 **Supplementary Data S9:** Refractory Inflammatory Arthritis Definition Components

149 Statistics

150 **Supplementary Figure S10:** Example selection of components for inclusion or

151 exclusion from included domain

152 **Supplementary Table S11:** Assessments initially mapped onto Refractory

153 Inflammatory Arthritis definition

154 **Supplementary Tables S12:** A) Data capture and synthesis of measures used in the

155 RIA definition across RA/JIA Biologic registries/cohort (Location, Condition and Parts

156 One and Two). B) Data capture and synthesis of measures used in the RIA definition

157 across RA/JIA Biologic registries/cohort (Part Three)

158

## 159 **References**

- 160 1. Chaplin H, Carpenter L, Raz A, Nikiphorou E, Lempp H, Norton S.  
161 Summarizing current refractory disease definitions in rheumatoid arthritis and  
162 polyarticular juvenile idiopathic arthritis: systematic review. *Rheumatology*.  
163 2021;60(8):3540-52.
- 164 2. Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes  
165 MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. *Annals of the*  
166 *Rheumatic Diseases*. 2020;80:31-5.
- 167 3. Polido-Pereira J, Vieira-Sousa E, Fonseca JE. Rheumatoid arthritis: what is  
168 refractory disease and how to manage it? *Autoimmun Rev*. 2011;10(11):707-13.
- 169 4. Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, et al.  
170 Biologic refractory disease in rheumatoid arthritis: results from the British Society for  
171 Rheumatology Biologics Register for Rheumatoid Arthritis. *Ann Rheum Dis*.  
172 2018;77(10):1405-12.
- 173 5. Buch MH. Defining refractory rheumatoid arthritis. *Annals of the Rheumatic*  
174 *Diseases*. 2018;77(7):966-9.
- 175 6. Zembrzuska H, Kumar B. Further Considerations of the Need for Integrated  
176 Mental Health Treatment in Rheumatoid Arthritis Patients: Comment on the Review  
177 by Matcham et al. *Arthritis & Rheumatology*. 2019;71(6):1024-5.
- 178 7. Carpenter L, Nikiphorou E, Kiely PDW, Walsh DA, Young A, Norton S.  
179 Secular changes in the progression of clinical markers and patient-reported  
180 outcomes in early rheumatoid arthritis. *Rheumatology*. 2020;59(9):2381-91.
- 181 8. Schoemaker CG, de Wit MPT. Treat-to-Target From the Patient Perspective  
182 Is Bowling for a Perfect Strike. *Arthritis & Rheumatology*. 2021;73(1):9-11.

## Refractory Inflammatory Arthritis revised definition and model

- 183 9. Radner H, Yoshida K, Frits M, Iannaccone C, Shadick NA, Weinblatt M, et al.  
184 The impact of multimorbidity status on treatment response in rheumatoid arthritis  
185 patients initiating disease-modifying anti-rheumatic drugs. *Rheumatology*.  
186 2015;54(11):2076-84.
- 187 10. Young A. Minutes from ARUK clinical study group refractory disease  
188 workshop: Prevalence of refractory disease in the UK. 2015.
- 189 11. Barbara Ansell National Network for Adolescent and young adult  
190 Rheumatology (BANNAR). BANNAR statement of understanding of current clinical  
191 practice for biologic and biosimilar use in JIA in the UK. 2017.
- 192 12. Armon K. Outcomes for juvenile idiopathic arthritis. *Paediatrics and Child  
193 Health*. 2018;28(2):64-72.
- 194 13. Fernandes S, Gomes JAM, Gomes SM, Martins F. Juvenile idiopathic  
195 arthritis: the transition to adulthood. *Pediatr Rheumatol Online J*. 2014;12(Suppl  
196 1):P193-P.
- 197 14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke  
198 JP. The Strengthening the Reporting of Observational Studies in Epidemiology  
199 (STROBE) statement: guidelines for reporting observational studies. *Lancet*.  
200 2007;370(9596):1453-7.
- 201 15. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi  
202 techniques. *International journal of clinical pharmacy*. 2016;38(3):655-62.
- 203 16. Chaplin H, Verhey I, Ng N, Galloway J, Scott I, Sen D, et al. AB0372  
204 Exploring Refractory Disease & Persistent Symptoms in RA/PolyJIA despite  
205 bDMARDs: Patient & Professional Experiences. *Annals of the Rheumatic Diseases*.  
206 2019;78(Suppl 2):1646-.
- 207 17. Leal I, Engebretson J, Cohen L, Rodriguez A, Wangyal T, Lopez G, et al.  
208 Experiences of paradox: a qualitative analysis of living with cancer using a  
209 framework approach. *Psycho-Oncology*. 2015;24(2):138-46.
- 210 18. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In:  
211 Bryman A, Burgess RG, editors. *Analyzing Qualitative Data*: Routledge; 1994.
- 212 19. Jellinek MS, McDermott JF. Formulation: Putting the Diagnosis Into a  
213 Therapeutic Context and Treatment Plan. *Journal of the American Academy of Child  
214 & Adolescent Psychiatry*. 2004;43(7):913-6.
- 215 20. Winters NC, Hanson G, Stoyanova V. The case formulation in child and  
216 adolescent psychiatry. *Child and adolescent psychiatric clinics of North America*.  
217 2007;16(1):111-32, ix.
- 218 21. Carroll S, Moon Z, Hudson J, Hulme K, Moss-Morris R. An Evidence-Based  
219 Theory of Psychological Adjustment to Long-Term Physical Health Conditions:  
220 Applications in Clinical Practice. *Psychosomatic Medicine*. 2022;84(5):547-59.
- 221 22. Leventhal H, Meyer U, Nerenz U. The common sense model of illness  
222 danger. In: Rachman S, editor. *Medical psychology*. 2. New York: Pergamon; 1980.  
223 p. 7–30.
- 224 23. Moss-Morris R. Adjusting to chronic illness: time for a unified theory. *Br J  
225 Health Psychol*. 2013;18(4):681-6.
- 226 24. Fernández-Ávila DG, Rojas MX, Rosselli D. The Delphi method in  
227 rheumatology research: are we doing it right? *Revista Colombiana de Reumatología  
228 (English Edition)*. 2020;27(3):177-89.
- 229 25. Hannan M, Katz PPE. Patient Outcomes in Rheumatology, 2020 A Review of  
230 Measures [Special Issue]. *Arthritis Care & Research*. 2020;72(S10):1-749.
- 231 26. Hill JC, Kang S, Benedetto E, Myers H, Blackburn S, Smith S, et al.  
232 Development and initial cohort validation of the Arthritis Research UK

## Refractory Inflammatory Arthritis revised definition and model

- 233 Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal  
234 care pathways. *BMJ open*. 2016;6(8).
- 235 27. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome  
236 in arthritis. *Arthritis Rheum*. 1980;23(2):137-45.
- 237 28. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status  
238 in children with juvenile rheumatoid arthritis. *Arthritis Rheum*. 1994;37(12):1761-9.
- 239 29. Halcomb E, Davidson P, Hardaker L. Using the consensus development  
240 conference method in healthcare research. *Nurse Res*. 2008;16(1):56-71.
- 241 30. Maher TM, Whyte MK, Hoyles RK, Parfrey H, Ochiai Y, Mathieson N, et al.  
242 Development of a Consensus Statement for the Definition, Diagnosis, and Treatment  
243 of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi  
244 Technique. *Adv Ther*. 2015;32(10):929-43.
- 245 31. Weerdesteijn KHN, Schaafsma FG, van der Beek AJ, Anema JR. Limitations  
246 to Work-Related Functioning of People with Persistent "Medically Unexplained"  
247 Physical Symptoms: A Modified Delphi Study Among Physicians. *J Occup Rehabil*.  
248 2017;27(3):434-44.
- 249 32. McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, et  
250 al. Development of a consensus core dataset in juvenile dermatomyositis for clinical  
251 use to inform research. *Annals of the Rheumatic Diseases*. 2018;77(2):241-50.
- 252 33. Diaz-Ledezma C, Higuera CA, Parvizi J. Success After Treatment of  
253 Periprosthetic Joint Infection: A Delphi-based International Multidisciplinary  
254 Consensus. *Clinical Orthopaedics and Related Research®*. 2013;471(7):2374-82.
- 255 34. Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content  
256 validity? Appraisal and recommendations. *Research in nursing & health*.  
257 2007;30(4):459-67.
- 258 35. Radner H, Dixon W, Hyrich K, Askling J. Consistency and Utility of Data Items  
259 Across European Rheumatoid Arthritis Clinical Cohorts and Registers. *Arthritis Care  
260 & Research*. 2015;67(9):1219-29.
- 261 36. Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Glerup M, et al. A survey  
262 of national and multi-national registries and cohort studies in juvenile idiopathic  
263 arthritis: challenges and opportunities. *Pediatric Rheumatology*. 2017;15(1):31.
- 264 37. Hiligsmann M, Rademacher S, Kaal KJ, Bansback N, Harrison M. The use of  
265 routinely collected patient-reported outcome measures in rheumatoid arthritis.  
266 *Seminars in Arthritis and Rheumatism*. 2018;48(3):357-66.
- 267 38. Young A. What have we learnt from early rheumatoid arthritis cohorts? *Best  
268 Practice & Research Clinical Rheumatology*. 2009;23(1):3-12.
- 269 39. Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C, et al.  
270 Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31  
271 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.  
272 *Annals of the Rheumatic Diseases*. 2022;81(10):1358-66.
- 273 40. Watts RA, Conaghan PG, Denton C, Foster HE, Isaacs J, Müller-Ladner U.  
274 *Oxford Textbook of Rheumatology*: Oxford University Press; 2013 2013-10.
- 275 41. EuroQol Group. EuroQol--a new facility for the measurement of health-related  
276 quality of life. *Health Policy*. 1990;16(3):199-208.
- 277 42. Sanderson TC, Hewlett SE, Flurey C, Dures E, Richards P, Kirwan JR. The  
278 Impact Triad (Severity, Importance, Self-management) as a Method of Enhancing  
279 Measurement of Personal Life Impact of Rheumatic Diseases. *The Journal of  
280 Rheumatology*. 2011;38(2):191-4.

## Refractory Inflammatory Arthritis revised definition and model

- 281 43. Codreanu C, Mogosan C, Ionescu R, Ancuta I, Opris D. Biologic therapy in  
282 rheumatoid arthritis: results from the Romanian registry of rheumatic diseases one  
283 year after initiation. *Farmacia*. 2014;62(6):1089-96.
- 284 44. Nordström DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K,  
285 Forsberg S, et al. Classic disease modifying anti-rheumatic drugs (DMARDs) in  
286 combination with infliximab. The Finnish experience. *Rheumatology International*.  
287 2006;26(8):741-8.
- 288 45. Canhão H, Faustino A, Martins F, Fonseca JE. Reuma.pt - the rheumatic  
289 diseases portuguese register. *Acta Reumatol Port*. 2011;36(1):45-56.
- 290 46. Kuijper TM, Luime JJ, Alves C, Barendregt PJ, van Zeben J, Bindels PJ, et al.  
291 Quality of life and health care use in patients with arthralgias without synovitis  
292 compared with patients diagnosed with early rheumatoid arthritis: data from an early  
293 arthritis cohort. *Arthritis Care & Research*. 2014;66(3):379-86.
- 294 47. Alves C, Luime JJ, van Zeben D, Huisman A-M, Weel AEAM, Barendregt PJ,  
295 et al. Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid  
296 arthritis and two diagnostic algorithms in an early arthritis clinic (REACH). *Annals of*  
297 *the rheumatic diseases*. 2011;70(9):1645-7.
- 298 48. Oen K, Tucker L, Huber AM, Miettunen P, Scuccimarri R, Campillo S, et al.  
299 Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a  
300 Canadian multicenter, prospective inception cohort study. *Arthritis Rheum*.  
301 2009;61(8):1077-86.
- 302 49. Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, McCROSKERY P,  
303 et al. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and  
304 utilization study: safety and etanercept utilization analyses from the RADIUS 1 and  
305 RADIUS 2 registries. *The Journal of rheumatology*. 2011;38(1):21-8.
- 306 50. Gerhold K, Richter A, Schneider M, Bergerhausen H-J, Demary W, Liebhaber  
307 A, et al. Health-related quality of life in patients with long-standing rheumatoid  
308 arthritis in the era of biologics: data from the German biologics register RABBIT.  
309 *Rheumatology*. 2015;54(10):1858-66.
- 310 51. Sokka T, Kautiainen H, Toloza S, Mäkinen H, Verstappen SMM, Lund Hetland  
311 M, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid  
312 arthritis seen in standard rheumatology care in 15 countries. *Annals of the*  
313 *Rheumatic Diseases*. 2007;66(11):1491-6.
- 314 52. Kvien TK, Uhlig T. The population based studies in rheumatoid arthritis. A  
315 method of longterm followup studies. *The Journal of Rheumatology*. 2004;69:35-40.
- 316 53. Minden K, Niewerth M, Listing J, Zink A. Health care provision in pediatric  
317 rheumatology in Germany--national rheumatologic database. *The Journal of*  
318 *Rheumatology*. 2002;29(3):622-8.
- 319 54. Olsen I, Haavardsholm E, Moholt E, Kvien T, Lie E. NOR-DMARD data  
320 management: implementation of data capture from electronic health records. *Clin*  
321 *Exp Rheumatol*. 2014;32(5 Suppl 85):158-62.
- 322 55. Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing  
323 disease activity and changing categories in a long-term nordic cohort study of  
324 juvenile idiopathic arthritis. *Arthritis Rheum*. 2011;63(9):2809-18.
- 325 56. Symmons D, Silman A. The norfolk arthritis register (NOAR). *Clinical and*  
326 *experimental rheumatology*. 2003;21(5; SUPP 31):S94-S9.
- 327 57. Druce KL, Jones GT, Macfarlane GJ, Verstappen SMM, Basu N. The  
328 Longitudinal Course of Fatigue in Rheumatoid Arthritis: Results from the Norfolk  
329 Arthritis Register. *The Journal of Rheumatology*. 2015;42(11):2059-65.

## Refractory Inflammatory Arthritis revised definition and model

- 330 58. Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid  
331 arthritis. *J Rheumatol Suppl.* 2004;69:14-21.
- 332 59. British Society of Rheumatology. National Early Inflammatory Arthritis Audit  
333 (NEIAA) 1st Annual Report 2019 [Available from:  
334 [https://www.rheumatology.org.uk/Portals/0/Documents/Practice\\_Quality/Audit/](https://www.rheumatology.org.uk/Portals/0/Documents/Practice_Quality/Audit/)].  
335 NEIA\_Audit\_report\_October\_2019.pdf. 2019.
- 336 60. Wolfe F, Michaud K. The National Data Bank for rheumatic diseases: a multi-  
337 registry rheumatic disease data bank. *Rheumatology (Oxford).* 2011;50(1):16-24.
- 338 61. Zink A, Listing J, Klindworth C, Zeidler H. The national database of the  
339 German Collaborative Arthritis Centres: I. Structure, aims, and patients. *Annals of*  
340 *the Rheumatic Diseases.* 2001;60(3):199-206.
- 341 62. van den Berg R, van der Heijde D, Landewé R, van Lambalgen K, Huizinga T.  
342 The METEOR initiative: the way forward for optimal, worldwide data integration to  
343 improve care for RA patients. *Clin Exp Rheumatol.* 2014;32(5 Suppl 85):S-135-40.
- 344 63. Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-  
345 term outcome of patients with JIA treated with etanercept, results of the biologic  
346 register JuMBO. *Rheumatology (Oxford).* 2012;51(8):1407-15.
- 347 64. Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al.  
348 Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in  
349 a large observational cohort study IORRA in Japan. *Modern Rheumatology.*  
350 2007;17(4):283-9.
- 351 65. Rayner L, Matcham F, Hutton J, Stringer C, Dobson J, Steer S, et al.  
352 Embedding integrated mental health assessment and management in general  
353 hospital settings: feasibility, acceptability and the prevalence of common mental  
354 disorder. *General Hospital Psychiatry.* 2014;36(3):318-24.
- 355 66. Matcham F, Norton S, Steer S, Hotopf M. Usefulness of the SF-36 Health  
356 Survey in screening for depressive and anxiety disorders in rheumatoid arthritis.  
357 *BMC Musculoskeletal Disorders.* 2016;17(1):224.
- 358 67. Sengler C, Klotsche J, Niewerth M, Liedmann I, Föll D, Heiligenhaus A, et al.  
359 The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an  
360 inactive disease state within the first year of specialised care: data from a German  
361 inception cohort. *RMD Open.* 2015;1(1):e000074.
- 362 68. Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM,  
363 Sacnun MP, et al. Early rheumatoid arthritis in Latin America: low socioeconomic  
364 status related to high disease activity at baseline. *Arthritis care & research.*  
365 2012;64(8):1135-43.
- 366 69. Lapadula G, Ferraccioli G, Ferri C, Punzi L, Trotta F. GISEA: an Italian  
367 biological agents registry in rheumatology. *Reumatismo.* 2011;63(3):155-64.
- 368 70. Young A, Dixey J, Williams P, Prouse P, Cox N, Kiely P, et al. An evaluation  
369 of the strengths and weaknesses of a register of newly diagnosed rheumatoid  
370 arthritis, 1986-2010. *Rheumatology (Oxford).* 2011;50(1):176-83.
- 371 71. de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA,  
372 et al. The prevalence of clinical remission in RA patients treated with anti-TNF:  
373 results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.  
374 *Rheumatology (Oxford).* 2012;51(9):1610-7.
- 375 72. Ibfelt EH, Jensen DV, Hetland ML. The Danish nationwide clinical register for  
376 patients with rheumatoid arthritis: DANBIO. *Clin Epidemiol.* 2016;8:737-42.
- 377 73. Kremer JM. The Corrona US registry of rheumatic and autoimmune diseases.  
378 *Clin Exp Rheumatol.* 2016;34(5 Suppl 101):S96-s9.

## Refractory Inflammatory Arthritis revised definition and model

- 379 74. Uitz E, Fransen J, Langenegger T, Stucki G. Clinical quality management in  
380 rheumatoid arthritis: putting theory into practice. *Rheumatology*. 2000;39(5):542-9.
- 381 75. Eriksson JK, Askling J, Arkema EV. The Swedish Rheumatology Quality  
382 Register: optimisation of rheumatic disease assessments using register-enriched  
383 data. *Clin Exp Rheumatol*. 2014;32(5 Suppl 85):S-147-9.
- 384 76. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius  
385 N, et al. Swedish registers to examine drug safety and clinical issues in RA. *Ann*  
386 *Rheum Dis*. 2006;65(6):707-12.
- 387 77. Önen F, Can G, Çapar S, Dalkılıç E, Pehlivan Y, Şenel S, et al. A real-life  
388 analysis of patients with rheumatologic diseases on biological treatments: Data from  
389 TURKBIO Registry. *Eur J Rheumatol*. 2022;9(2):82-7.
- 390 78. Marcos J, Waimann C, Dal Pra F, Hogrefe J, Retamozo S, Caeiro F, et al.  
391 General characteristics of an early arthritis cohort in Argentina. *Rheumatology*.  
392 2010;50(1):110-6.
- 393 79. Bykerk VP, JAMAL S, BOIRE G, HITCHON CA, HARAOUY B, POPE JE, et al.  
394 The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis  
395 Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR  
396 Classification Criteria Present with Less Severe Disease Activity. *The Journal of*  
397 *Rheumatology*. 2012;39(11):2071-80.
- 398 80. Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, et al.  
399 The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry:  
400 design, rationale, and characteristics of patients enrolled in the first 12 months.  
401 *Pediatric Rheumatology*. 2017;15(1):30.
- 402 81. Adib N, Hyrich K, Thornton J, Lunt M, Davidson J, Gardner-Medwin J, et al.  
403 Association between duration of symptoms and severity of disease at first  
404 presentation to paediatric rheumatology: results from the Childhood Arthritis  
405 Prospective Study. *Rheumatology*. 2008;47(7):991-5.
- 406 82. Hanns L, Cordingley L, Galloway J, Norton S, Carvalho LA, Christie D, et al.  
407 Do depressive symptoms at disease onset associate with future disease activity for  
408 adolescent patients with JIA? Results from the Childhood Arthritis Prospective Study  
409 (CAPS). *Annals of Rheumatic Disease*. 2016;75((Suppl2)):171.
- 410 83. McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster  
411 HE, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in  
412 children with new-onset juvenile idiopathic arthritis. *Ann Rheum Dis*.  
413 2013;72(12):1983-8.
- 414 84. Hyrich K. STUDY PROTOCOL British Society for Rheumatology Biologics  
415 Register for Rheumatoid Arthritis (BSRBR-RA) v2.0\_05122018. 2018.
- 416 85. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, et al. Using  
417 genetic and clinical data to understand response to disease-modifying anti-rheumatic  
418 drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis  
419 Sequential Study. *Rheumatology*. 2010;50(1):40-6.
- 420 86. Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, et al.  
421 Effectiveness and Safety of Infliximab in Rheumatoid Arthritis: Analysis From a  
422 Canadian Multicenter Prospective Observational Registry. *Arthritis Care & Research*.  
423 2014;66(8):1142-51.
- 424 87. Rotar Z, Hočevar A, Rebolj Kodre A, Praprotnik S, Tomšič M. Retention of the  
425 second-line biologic disease-modifying antirheumatic drugs in patients with  
426 rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the  
427 BioRx.si registry. *Clin Rheumatol*. 2015;34(10):1787-93.

## Refractory Inflammatory Arthritis revised definition and model

- 428 88. Rintelen B, Zwerina J, Herold M, Singer F, Hitzelhammer J, Halder W, et al.  
429 Validity of data collected in BIOREG, the Austrian register for biological treatment in  
430 rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.  
431 BMC Musculoskeletal Disorders. 2016;17(1):358.
- 432 89. Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al.  
433 Associations of disease activity and treatments with mortality in men with rheumatoid  
434 arthritis: results from the VARA registry. Rheumatology. 2010;50(1):101-9.
- 435 90. Kovalchik SA, Charles-Schoeman C, Khanna D, Paulus HE. An association  
436 study of disease activity score components and patient satisfaction with overall  
437 health for early RA patients on non-biologic DMARD therapy. Rheumatol Int.  
438 2012;32(9):2725-9.
- 439 91. Otten MH, Prince FHM, Anink J, ten Cate R, Hoppenreijns EPAH, Armbrust W,  
440 et al. Effectiveness and safety of a second and third biological agent after failing  
441 etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC  
442 Register. Annals of the Rheumatic Diseases. 2013;72(5):721-7.
- 443 92. Barnabe C, Crane L, White T, Hemmelgarn B, Kaplan GG, Martin L, et al.  
444 Patient-reported Outcomes, Resource Use, and Social Participation of Patients with  
445 Rheumatoid Arthritis Treated with Biologics in Alberta: Experience of Indigenous and  
446 Non-indigenous Patients. The Journal of Rheumatology. 2018;45(6):760-5.
- 447 93. Nüßlein HG, Alten R, Galeazzi M, Lorenz H-M, Boumpas D, Nurmohamed  
448 MT, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in  
449 European and Canadian populations: a 6-month interim analysis of the 2-year,  
450 observational, prospective ACTION study. BMC Musculoskeletal Disorders.  
451 2014;15(1):14.
- 452 94. Horák P, Skácelová M, Hejduk K, Smržová A, Pavelka K. Abatacept and its  
453 use in the treatment of rheumatoid arthritis (RA) in the Czech Republic—data from  
454 the ATTRA registry. Clinical Rheumatology. 2013;32(10):1451-8.
- 455 95. Williams MP, Buchbinder R, March L, Lassere M. The Australian  
456 Rheumatology Association Database (ARAD). Seminars in Arthritis and  
457 Rheumatism. 2011;40(4):e2-e3.
- 458 96. Singh G. Arthritis, Rheumatism and Aging Medical Information System Post-  
459 Marketing Surveillance Program. The Journal of Rheumatology. 2001;28(5):1174-9.
- 460 97. Karateev D, Satybaldyev A, Luchikhina E, Lukina G, Nasonov E, Artyomov A,  
461 et al. AB1115 The Characteristics of Therapy of Patients with Rheumatoid Arthritis in  
462 the Russian Federation According to the Russian Register. Annals of the Rheumatic  
463 Diseases. 2015;74:1273.3-4.
- 464 98. Hafström I, Ajeganova S, Andersson ML, Bala SV, Bergman S, Bremander A,  
465 et al. A Swedish register-based, long-term inception cohort study of patients with  
466 rheumatoid arthritis - results of clinical relevance. Open access rheumatology :  
467 research and reviews. 2019;11:207-17.
- 468 99. Kearsley-Fleet L, Davies R, Baidam E, Beresford MW, Foster HE, Southwood  
469 TR, et al. Factors associated with choice of biologic among children with Juvenile  
470 Idiopathic Arthritis: results from two UK paediatric biologic registers. Rheumatology.  
471 2016;55(9):1556-65.
- 472 100. Hyrich K. CURRENT DOCUMENT LIST – Biologics for Children with  
473 Rheumatic Diseases (BCRD). 2022.
- 474 101. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al.  
475 Safety and efficacy of combination of etanercept and methotrexate compared to  
476 treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA):  
477 preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519-25.




## Refractory Inflammatory Arthritis revised definition and model

- 478 102. Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G. Improvement  
479 in health-related quality of life for children with juvenile idiopathic arthritis after start  
480 of treatment with etanercept. *Arthritis Care Res (Hoboken)*. 2014;66(2):253-62.
- 481 103. Sanchez-Piedra C, Hernández Miguel MV, Manero J, Roselló R, Sánchez-  
482 Costa JT, Rodríguez-Lozano C, et al. Objectives and methodology of BIOBADASER  
483 phase III. *Reumatología Clínica (English Edition)*. 2019;15(4):229-36.
- 484 104. Cuppen BVJ, Fu J, van Wietmarschen HA, Harms AC, Koval S, Marijnissen  
485 ACA, et al. Exploring the Inflammatory Metabolomic Profile to Predict Response to  
486 TNF- $\alpha$  Inhibitors in Rheumatoid Arthritis. *PLOS ONE*. 2016;11(9):e0163087.
- 487 105. Hays RD, Sherbourne CD, Mazel RM. The rand 36-item health survey 1.0.  
488 *Health Economics*. 1993;2(3):217-27.
- 489 106. Felson DT, Feathers V, Naik C, Solomon DH, Weinblatt ME, Shadick N.  
490 Meaning of patient global assessment when joint counts are low in rheumatoid  
491 arthritis. *RMD Open*. 2022;8(2):e002346.
- 492 107. Osei-Bimpong A, Meek JH, Lewis SM. ESR or CRP? A comparison of their  
493 clinical utility. *Hematology*. 2007;12(4):353-7.
- 494 108. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al.  
495 American College of Rheumatology/European League against Rheumatism  
496 provisional definition of remission in rheumatoid arthritis for clinical trials. *Ann Rheum*  
497 *Dis*. 2011;70(3):404-13.
- 498 109. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW,  
499 van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid  
500 arthritis: first step in the development of a disease activity score. *Ann Rheum Dis*.  
501 1990;49(11):916-20.
- 502 110. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A  
503 simplified disease activity index for rheumatoid arthritis for use in clinical practice.  
504 *Rheumatology (Oxford)*. 2003;42(2):244-57.
- 505 111. Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L,  
506 et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a  
507 patient-derived composite measure of impact of rheumatoid arthritis: a EULAR  
508 initiative. *Annals of the Rheumatic Diseases*. 2011;70(6):935-42.
- 509 112. Hazes JM, Hayton R, Silman AJ. A reevaluation of the symptom of morning  
510 stiffness. *J Rheumatol*. 1993;20(7):1138-42.
- 511 113. Boonstra AM, Schiphorst Preuper HR, Balk GA, Stewart RE. Cut-off points for  
512 mild, moderate, and severe pain on the visual analogue scale for pain in patients  
513 with chronic musculoskeletal pain. *Pain*. 2014;155(12):2545-50.
- 514 114. Nicklin J, Cramp F, Kirwan J, Greenwood R, Urban M, Hewlett S. Measuring  
515 fatigue in rheumatoid arthritis: A cross-sectional study to evaluate the Bristol  
516 Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales,  
517 and numerical rating scales. *Arthritis Care & Research*. 2010;62(11):1559-68.
- 518 115. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in  
519 rheumatoid arthritis reflects pain, not disease activity. *Rheumatology (Oxford)*.  
520 2006;45(7):885-9.
- 521 116. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). *Clin Exp*  
522 *Rheumatol*. 2005;23(5 Suppl 39):S14-8.
- 523 117. Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment  
524 Scale: a simple measure of impairment in functioning. *The British Journal of*  
525 *Psychiatry*. 2002;180(5):461-4.


## Refractory Inflammatory Arthritis revised definition and model

- 526 118. Silke L, Kirresh O, Sturt J, Lempp H. Development of the Rheumatoid Arthritis  
527 Distress Scale (RADS) – A New Tool to Identify Disease-Specific Distress in Patients  
528 with Rheumatoid Arthritis. 2021;5(51):1-21.
- 529 119. Becede M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, et al.  
530 Risk profiling for a refractory course of rheumatoid arthritis. *Semin Arthritis Rheum.*  
531 2019;49(2):211-7.
- 532 120. Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-  
533 inflammatory mechanisms in refractory rheumatoid arthritis. *Nature Reviews*  
534 *Rheumatology.* 2021;17:17-33.
- 535 121. Melville AR, Kearsley-Fleet L, Buch MH, Hyrich KL. Understanding Refractory  
536 Rheumatoid Arthritis: Implications for a Therapeutic Approach. *Drugs.*  
537 2020;80(9):849-57.
- 538 122. Lopez-Olivo MA, Zogala RJ, des Bordes J, Zamora NV, Christensen R, Rai D,  
539 et al. Outcomes Reported in Prospective Long-Term Observational Studies and  
540 Registries of Patients with Rheumatoid Arthritis Worldwide: An OMERACT  
541 Systematic Review. *Arthritis Care & Research.* 2020;n/a(n/a).
- 542 123. Machado PM. Measurements, composite scores and the art of ‘cutting-off’.  
543 *Annals of the Rheumatic Diseases.* 2016;75(5):787-90.
- 544 124. Messelink MA, Roodenrijs NMT, van Es B, Hulsbergen-Veelken CAR, Jong S,  
545 Overmars LM, et al. Identification and prediction of difficult-to-treat rheumatoid  
546 arthritis patients in structured and unstructured routine care data: results from a  
547 hackathon. *Arthritis Research & Therapy.* 2021;23(1):184.
- 548 125. Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, Lafeber FPJG,  
549 Jacobs JWG, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and  
550 burden of disease. *Rheumatology.* 2020;60(8):3778-88.

551



### Round One Domains Inclusion



### Round Two Components Inclusion

